Over 28 million Surgeries Canceled Around the World Because of COVID-19
Orthopedic surgeries are the ones most likely to be canceled.
As more states in the U.S. begin to allow elective surgery, a modeling study published in the British Journal of Surgery estimates that 28.4 million elective surgeries will be canceled or postponed this year because of COVID-19.
The model, which is based on information collected from 359 hospitals and 71 countries and then extended to cover 190 countries, estimates that each additional week of COVID-19-related “disruption” to hospital services results in 2.4 million cancellations.
Constructed by researchers at the University of Birmingham in Great Britain, the model projects that orthopedic procedures will top the list of the type of surgeries that will be canceled.
Meanwhile, in the U.S., individual states started to allow elective surgeries to be performed starting in late April. In many states, health officials have attached conditions to the permission to resume elective surgeries, such as having an ample supply of PPE on hand.
Yesterday Gov. Andrew Cuomo of New York announced that elective surgeries could begin in 12 more counties, bringing the total to 47 of the state’s 62 counties.
Breaking Down Health Plans, HSAs, AI With Paul Fronstin of EBRI
November 19th 2024Featured in this latest episode of Tuning In to the C-Suite podcast is Paul Fronstin, director of health benefits research at EBRI, who shed light on the evolving landscape of health benefits with editors of Managed Healthcare Executive.
Listen
In this latest episode of Tuning In to the C-Suite podcast, Briana Contreras, an editor with MHE had the pleasure of meeting Loren McCaghy, director of consulting, health and consumer engagement and product insight at Accenture, to discuss the organization's latest report on U.S. consumers switching healthcare providers and insurance payers.
Listen
Prime Therapeutics Finds No Medical Cost Offsets for GLP-1 Obesity Drugs | AMCP Annual 2025
April 1st 2025A Prime Therapeutics analysis of real-world data has found that medical costs for patients taking GLP-1 drugs for obesity had increased by about $1,338 per member, compared with a matched control group.
Read More
